Compugen Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of Matter Patent in China
Compugen Ltd. (CGEN) has received a new patent from the China National Intellectual Property Administration for COM902, an immuno-oncology therapeutic antibody targeting TIGIT. This patent extends the protection for COM902 beyond existing patents in the U.S. and Europe and covers its composition for cancer treatment. The patent is valid until at least August 2037. COM902 is currently in a Phase 1 clinical trial, showing potential to enhance T cell responses against tumors when combined with PD-1 inhibitors. This development reflects Compugen's commitment to expanding its immuno-oncology pipeline.
- Granted new patent in China for COM902, extending market exclusivity.
- Patent offers composition protection that expands beyond the U.S. and Europe.
- COM902 shows potential in Phase 1 trials for enhancing T cell responses.
- None.
HOLON, Israel, Nov. 2, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the China National Intellectual Property Administration (CNIPA) has granted the Company a new patent covering the composition of matter of COM902, its immuno-oncology therapeutic antibody targeting TIGIT.
China Patent No. CN 110088132 B, titled "Anti-TIGIT Antibodies, Anti-PVRIG Antibodies and Combinations Thereof," relates to the composition of matter of COM902, alone or in combination with a second antibody targeting an immune checkpoint, including PD-1 and PVRIG (specifically COM701). The patent further relates to the COM902 antibody composition for use in treating cancer by activating T cells. This patent is expected to expire no earlier than August 2037 in the China.
This first patent issued in China expands the intellectual property protection for COM902 beyond the United States and Europe where similar composition of matter and use patents have been granted. This patent, as well as other patents the Company is pursuing for COM902, are part of Compugen's global intellectual property and patent strategy across its innovative immuno-oncology pipeline.
About COM902
COM902 is a high affinity, fully human antibody that blocks the interaction of TIGIT with PVR, its ligand, and consequently enhances T cell function. It is currently being evaluated in a Phase 1 clinical trial in patients with advanced malignancies who have exhausted all available standard therapies. Compugen has demonstrated in preclinical studies that simultaneous inhibition of TIGIT and PVRIG, the two coinhibitory arms of the DNAM axis, can increase antitumor immune responses, which may be further enhanced with the addition of PD-1 blockade. These data suggest that treatment with COM701 and COM902, targeting PVRIG and TIGIT, respectively, alone or in combination with a PD-1 inhibitor, has the potential to expand immuno-oncology treatment to patient populations who are non-responsive or refractory to existing immunotherapies.
The discovery of TIGIT, using the Company's computational discovery platform, was published by Compugen in October 2009 in the Proceedings of the National Academy of Sciences (PNAS).
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. The Company's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. The Company's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Compugen. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements regarding the expected expiration date of the patent in China. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's operations could be affected by the outbreak and spread of COVID-19, clinical development involves a lengthy and expensive process, with an uncertain outcome and Compugen may encounter substantial delays or even an inability to begin clinical trials for any specific product, or may not be able to conduct or complete its trials on the timelines it expects; Compugen relies, and expects to continue to rely, on third parties to conduct its clinical trials and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the COVID-19); Compugen's business model is substantially dependent on entering into collaboration agreements with third parties; Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; and patent reform and other legislative changes in certain territories may affect Compugen's ability to obtain and enforce its patents. These risks and other risks are fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124
Investor Relations contact:
Bob Yedid
LifeSci Advisors, LLC
Email: bob@lifesciadvisors.com
Tel: +1 (646) 597-6989
Media contact:
Josephine Belluardo, Ph.D.
LifeSci Communications
Email: jo@lifescicomms.com
Tel: +1 (646) 751-4361
View original content:http://www.prnewswire.com/news-releases/compugen-further-expands-patent-portfolio-for-tigit-inhibitor-com902-with-composition-of-matter-patent-in-china-301164783.html
SOURCE Compugen Ltd.
FAQ
What is the new patent granted to Compugen (CGEN) in China?
How long is the new patent for COM902 expected to last?
What is the significance of the COM902 patent for Compugen (CGEN)?
What clinical trials is COM902 currently undergoing?
How does COM902 work in cancer treatment?
